Stephens T C, Peacock J H
Br J Cancer Suppl. 1980 Apr;4:288-93.
The response of the B16 melanoma to the simultaneous combination of CY plus CCNU was examined using cell survival and growth delay endpoints. Combination data were evaluated either by applying the simple concept that an additive combination response is equal to the sum of the single agent responses or by constructing additivity envelopes as described recently by Steel & Peckham (1979), in order to take account of non-linear dose-response curves. Although cell survival was additive on the simple basis, tumour growth delay was greater than predicted by the simple concept, but still within the additivity envelopes. This apparent anomaly may, however, be explained by considering the relationship between the two endpoints. Although the extent of growth delay of a tumour is dependent on the level of tumor cell survival, it is also influenced by other factors such as the rate of regrowth of surviving tumour cells, which may in turn be affected by systemic host effects resulting from the same treatment. We have recently shown that tumour cell repopulation after CY treatment is much slower than after CCNU, and in this paper we demonstrate by means of a transplantation experiment that this is probably due to a systemic host effect of CY. Thus, the observed growth delay response of the combination is consistent with a model in which the agents produce additive cell killing, but the subsequent tumour cell repopulation is retarded by a systemic effect of CY.
使用细胞存活和生长延迟终点来研究B16黑色素瘤对环磷酰胺(CY)加洛莫司汀(CCNU)联合治疗的反应。联合治疗数据的评估,要么采用简单的概念,即相加性联合反应等于单药反应之和,要么按照Steel和Peckham(1979年)最近描述的方法构建相加性包络线,以便考虑非线性剂量反应曲线。虽然在简单基础上细胞存活是相加性的,但肿瘤生长延迟比简单概念预测的要大,但仍在相加性包络线范围内。然而,这种明显的异常现象可以通过考虑两个终点之间的关系来解释。虽然肿瘤生长延迟的程度取决于肿瘤细胞存活水平,但它也受到其他因素的影响,如存活肿瘤细胞的再生长速率,而这反过来可能会受到同一治疗引起的全身宿主效应的影响。我们最近表明,CY治疗后肿瘤细胞的再增殖比CCNU治疗后要慢得多,在本文中,我们通过移植实验证明这可能是由于CY的全身宿主效应。因此,观察到的联合治疗生长延迟反应与一种模型一致,即药物产生相加性细胞杀伤作用,但随后肿瘤细胞的再增殖受到CY全身效应的抑制。